Unique ID issued by UMIN | UMIN000042584 |
---|---|
Receipt number | R000048606 |
Scientific Title | Pharmacological risk factor for gastrointestinal bleeding after endoscopic submucosal dissection in gastric cancer patients with direct oral anticoagulants |
Date of disclosure of the study information | 2020/11/27 |
Last modified on | 2023/05/29 19:40:53 |
Pharmacological risk factor for gastrointestinal bleeding after endoscopic submucosal dissection in gastric cancer patients with direct oral anticoagulants
Pharmacological risk factor for bleeding after ESD in patients with DOAC
Pharmacological risk factor for gastrointestinal bleeding after endoscopic submucosal dissection in gastric cancer patients with direct oral anticoagulants
Pharmacological risk factor for bleeding after ESD in patients with DOAC
Japan |
Early-stage gastric cancer patients treated with DOAC
Gastroenterology |
Malignancy
NO
To clarify a risk factor for bleeding after ESD for early-stage gastric cancer in patients treated with DOAC
Safety,Efficacy
Association with plasma concentration of DOAC at trough or anti-Xa activity and incidence of bleeding after ESD for early-stage gastric cancer in patients treated with DOAC
(1) Effect of drug blood concentration (Xa activity) of DOAC (Tmax) on gastrointestinal bleeding after ESD for early gastrointestinal cancer in DOAC users
(2) Influence of drug-metabolizing enzyme gene polymorphisms on post-ESD gastrointestinal bleeding in early gastrointestinal cancer
(3) Effect of blood coagulation markers on gastrointestinal bleeding after ESD in early gastrointestinal cancer
(4) Extraction of endoscopic features of early gastrointestinal tract for gastrointestinal bleeding after ESD in early gastrointestinal cancer
(5) Extraction of pathological features of early gastrointestinal tract for gastrointestinal bleeding after ESD in early gastrointestinal cancer
(6) Association of CHADs score with post-ESD gastrointestinal bleeding in early gastrointestinal cancer
Observational
20 | years-old | <= |
Not applicable |
Male and Female
1. With consent
2. Performance status: ECOG 0 or 1
3. Early stage gastric cancer according to the treatment guideline for gastric cancer by the Japanese association of gastric cancer.
4. Over 20 years old patients treated with DOAC
1. No consent
2. with three kinds of anticoagulants
3. with severe diseases (heart, liver and pulmonary failure)
4. Pregnancy
115
1st name | Mitsushige |
Middle name | |
Last name | Sugimoto |
Tokyo Medical University Hospital
Department of Gastroenterological Endoscopy
160-8402
6-1-1 Shinjuku, Shinjuku-ku,Tokyo
0333516141
mura05310531@gmail.com
1st name | Masaki |
Middle name | |
Last name | Masaki |
National Hospital Organization Kyoto Medical Center
Department of Gastroenterology
6128555
1-1 Mukouhata-cho, Fukakusa, Fushimi-ku, Kyoto
0756419161
ds110674@outlook.jp
Department of Gastroenterological Endoscopy, Tokyo Medical University Hospital
no organization.
Other
Tokyo Medical University Hospital
6-1-1 Shinjuku, Shinjuku-ku,Tokyo
0333516141
mura05310531@gmail.com
NO
2020 | Year | 11 | Month | 27 | Day |
Unpublished
Open public recruiting
2020 | Year | 04 | Month | 01 | Day |
2020 | Year | 04 | Month | 30 | Day |
2020 | Year | 05 | Month | 01 | Day |
2023 | Year | 03 | Month | 31 | Day |
This research is a continuation of the previous research (UMIN000031930) conducted at Shiga University of Medical Science.
2020 | Year | 11 | Month | 27 | Day |
2023 | Year | 05 | Month | 29 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048606